To the Editor:
We read with great interest the study by Yamagata et al of percutaneous coronary intervention (PCI) using sirolimuseluting stents vs off-pump coronary artery bypass grafting (CABG) in diabetic patients with multivessel disease (MVD). 1 Despite a non-randomized retrospective analysis, however, any statistical adjustment (eg, propensity score analysis or Cox proportional hazards regression) was not applied in their study unfortunately. Regarding PCI using drug-eluting stents (DES) vs CABG in MVD, Benedetto et al 2 recently performed a meta-analysis on 24,268 patients from 9 observational non-randomized studies. Unadjusted hazard ratios (HRs) for outcomes of interest, however, were abstracted from several studies and combined in the meta-analysis. We focused on late mortality, the hardest outcome, and performed a metaanalysis of only high-quality observational studies providing adjusted HRs.
To identify all comparative studies of PCI using DES vs CABG enrolling patients with MVD, public domain databases including MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials were searched (current through April 2010) using Web-based search engines (PubMed, OVID). Studies considered for inclusion met the following criteria: the design was a comparative study (randomized trial or observational study); the study population was patients with MVD; patients were assigned to PCI using DES vs CABG (on-pump or off-pump); and main outcomes included adjusted (in case of observational studies) HRs for late (≥1 year) all-cause death. Our search identified 8 high-quality observational studies reporting adjusted HRs. We excluded 2 randomized trials (SYNTAX 3 and CARDia 4 ) because they enrolled patients with left main disease without MVD and complex single-vessel disease, respectively. Pooled analysis of the 14 HRs from the 8 studies (representing 29,252 patients) demonstrated a statistically significant 44% increase in mortality with PCI using DES relative to CABG in the randomeffects model (Figure; HR, 1.44; 95% confidence interval (CI), 1.15 to 1.82; P=0.002). There was significant between-
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study heterogeneity (P=0.02 by standard χ 2 tests), and little difference in the pooled result from fixed-effects modeling (HR, 1.37; 95% CI, 1.21 to 1.55; P<0.00001). Exclusion of any single study from the analysis did not substantively alter the overall result of our analysis. Relative to CABG, PCI using DES for 2-vessel disease (VD) and 3VD was associated with respectively a statistically non-significant 32% (HR, 1.32; 95% CI, 0.83 to 2.11; P=0.25) and significant 54% increase (HR, 1.54; 95% CI, 1.11 to 2.13; P=0.01) in mortality. There was no evidence of significant publication bias (P=0.58 by an adjusted rank-correlation test).
The results of our analysis suggest that PCI using DES may increase midterm mortality by more than 40% over CABG in patients with MVD, especially by 54% in those with 3VD. Observational studies reflect the more heterogeneous realworld clinical practice, and they should be considered to support the results from randomized trials and therefore in determining the standard of care for MVD patients. 2 To reduce the effect of treatment-selection bias and potential confounding in observational studies, however, rigorous adjustment for significant differences in the baseline characteristics of patients (eg, propensity score analysis) should be conducted. Furthermore, not unadjusted but adjusted estimates should be pooled also in a meta-analysis of observational studies. The present results, however, are unexpected, because in meta-analyses of randomized trials no significant differences were observed in follow-up mortality after PCI using DES vs bare-metal sterns 5 and following PCI using bare-metal sterns vs CABG for MVD. 6 Long-term results of a large-scale randomized trial are needed to confirm our findings.
